SEP 03, 2014 12:00 AM PDT

Thomson Reuters Analysis Finds High Market Potential in Depression Pharma Market

WRITTEN BY: Ilene Schneider
The Intellectual Property and Science business of Thomson Reuters released a three-part analysis on the depression drug market following the 25th anniversary of the U.S. launch of the iconic antidepressant Prozac. Now, just beyond a quarter-century later, Thomson Reuters analysts have found a considerable amount of untapped potential for the pharmaceutical industry to develop treatments for managing the debilitating condition of depression.

The 1988 U.S. launch of Prozac inspired a revolution in the depression treatment landscape; not only did it excel to a blockbuster level - in just two years becoming the world's most prescribed medication - but also it became a pop-culture phenomenon with books, magazines, movies and television, making it a household name and driving patients to request prescriptions from their doctors. Prozac ushered in an era of a new class of drugs that helped destigmatize depression and treat more people suffering from it.

Now, a year past this significant milestone, Thomson Reuters analysts studied the widespread effects of this critical drug and the current state of the depression treatment environment by performing three unique analyses:

25 Years After Prozac, an infographic illustrating a timeline from the 1988 launch to a current outlook at the condition's prevalence rates and drug, patent and deal landscapes
Spotlight on Depression, an in-depth report exploring the challenges and opportunities facing the depression drug market and a look at its current leaders
Battling Depression: Research Highlights, a view into the dominant research around treatments for depression

The analysts found a substantial number of possibilities for the pharmaceutical market for developing new treatments for the management of depression. It remains a significant global health issue. According to the World Health Organization, depression affects as many as 350 million people worldwide and is the leading cause of disability in the world. Fewer than half of sufferers receive treatment; in some countries, that figure falls to fewer than one in 10. The U.S. Centers for Disease Control and Prevention found that more than 9 percent of Americans currently suffer from the disorder. The high incidence rate, combined with limited market penetration, continues to make depression a market with significant potential.

The analysts also found that despite the growing market opportunities, companies developing drugs for depression face several challenges. The abundance of generic options has played a role in halving the value of branded antidepressants over the years. In addition, antidepressants carry a black-box warning regarding the increased risk of suicide in children, adolescents and young adults, which limits their use among that population. Changes to medication also present a problem, as does psychosocial treatment, which remains the preferred first line of therapy.

"Depression is widespread, but clinicians still lack a complete understanding of the condition, which presents hurdles in pharmaceutical development," said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. "There are millions of people around the world who suffer from depression every day. The aim of this report is to shed a unique perspective on the evolution of depression therapies in hopes that it incents the industry to identify new ways to help depression sufferers manage their condition."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 26, 2020
Cell & Molecular Biology
APR 26, 2020
Nose Cells Found to Be Likely SARS-CoV-2 Entry Points
This work may help explain why the virus is so easy to transmit.
APR 26, 2020
Cannabis Sciences
APR 26, 2020
History of Cannabis Dependence Goes Hand in Hand with Poor Mental Health
As legal restrictions loosen around the recreational use of cannabis, researchers are becoming increasingly concerned ab ...
MAY 08, 2020
Immunology
MAY 08, 2020
Vaccine Prevents Virally-induced Type 1 Diabetes
Scientists aren’t exactly sure what causes type 1 diabetes, although genetics and environmental factors are presum ...
MAY 12, 2020
Genetics & Genomics
MAY 12, 2020
Learning More About Why Some Diseases Have a Sex Bias
The biological differences between men and women go beyond the things we're aware of like the sex chromosomes and hormon ...
MAY 18, 2020
Microbiology
MAY 18, 2020
An Antibody Against SARS May Neutralize SARS-CoV-2
SARS-CoV caused an outbreak of SARS in 2003. Samples collected from those patients back then may help us against SARS-Co ...
MAY 22, 2020
Health & Medicine
MAY 22, 2020
Smart Speakers can Identify Cardiac Arrest
Smart devices can control your lights, make your grocery list, and play songs on command. Researchers are now developing ...
Loading Comments...